Shukra Pharmaceuticals Limited has announced a significant step in its business journey through a new collaboration. The company has entered into a strategic non-exclusive PAN India distribution agreement with Wockhardt Limited, a renowned global pharmaceutical company.
This tie-up strengthens Shukra Pharmaceuticals' presence in institutional healthcare networks and highlights its growth momentum in both operations and financial performance.
The agreement became effective on September 9, 2025 and will remain valid until March 2026. Under this arrangement, Shukra Pharmaceuticals is authorised to quote products, collect order copies, raise invoices, and collect payments directly on behalf of Wockhardt Limited.
The products include advanced anti-infective formulations such as EMROK® (Levonadifloxacin) and MIQNAF® (Nafithromycin). These antibiotics are developed to combat critical infections and are distributed across ESIC/ESIS hospitals and Defence/AFMSD/DGAFMS units throughout India.
Speaking on this development, the management of Shukra Pharmaceuticals said, “We are proud to partner with Wockhardt Limited in delivering advanced, high-quality antibiotics to hospitals across India. This collaboration not only strengthens our market presence but also supports India’s expanding healthcare infrastructure, benefiting patients and stakeholders alike.”
This collaboration enhances Shukra Pharmaceuticals' reach across institutional and government healthcare networks in India. It supports revenue visibility and creates a stronger operational footprint, while aligning with the country’s expanding healthcare infrastructure.
The company has registered robust growth in its latest results. For the quarter ending June 2025 (Q1 FY26), Shukra Pharmaceuticals reported ₹5.39 crore in revenue from operations, a 69.5% year-on-year increase compared to ₹3.18 crore in Q1 FY25. Net profit rose to ₹1.03 crore in Q1 FY26, marking a 110.2% increase from ₹49 lakhs in the same quarter last year.
Read More: Cabinet Clears ₹3,169 Cr Rail Project: Bhagalpur–Dumka–Rampurhat Line to Be Doubled!
On September 10, 2025, Shukra Pharmaceuticals share price hit the upper circuit of 2% at ₹27.24.
Incorporated in 1993, Shukra Pharmaceuticals Limited is engaged in manufacturing and marketing pharmaceutical products along with laboratory testing. The company operates a fully integrated plant in Rakanpor, Kalol, Gandhinagar and has an internationally accredited laboratory in Ahmedabad.
Its operations cover Contract Manufacturing, Loan Licence, and Domestic as well as International operations. Backed by a team of research analysts, medical officers, and technical experts, the company maintains stringent quality standards across all its products.
This strategic agreement with Wockhardt reinforces Shukra Pharmaceuticals growth journey and its commitment to supporting India’s healthcare sector.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Sep 10, 2025, 4:05 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
